New Challenges for Hypertension Treatment

被引:9
作者
Rosas-Peralta, Martin [1 ]
Marcela Jimenez-Genchi, Gladys [2 ]
机构
[1] Inst Mexicano Seguro Social, Ctr Med Nacl Siglo 21, Programa A Todo Corazon Codigo Infarto, Jefe Area Med, Mexico City, DF, Mexico
[2] Inst Mexicano Seguro Social, Ctr Med Nacl Siglo 21, Programa A Todo Corazon, Mexico City, DF, Mexico
关键词
Hypertension; Guidelines; Therapy; Mexico; ASSOCIATION TASK-FORCE; CLINICAL-PRACTICE GUIDELINES; SYSTOLIC BLOOD-PRESSURE; AMERICAN-COLLEGE; CARDIOVASCULAR RISK; GLOBAL BURDEN; TRIAL; METAANALYSIS; PREVENTION; MANAGEMENT;
D O I
10.1016/j.arcmed.2018.11.005
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
In Mexico around 22.3 million adult Mexicans have hypertension. An estimated 65 million adult Americans, or nearly one in four of the adult population of the United States, have hypertension. However, with the new classification from 2017 ACC/AHA guidelines which considered >= 130/80 mmHg as the new cutoff point to diagnosis of hypertension, the number of patients is at least twice, in other words around 40 million adult Mexicans potentially have hypertension. Although this new classification is directed to be more efficient in the changes of life style and nondrug strategies to stage one hypertension the real word evidence suggest that we need to be more careful in the selection of patients to be introduced in a drug therapy strategy. Elevations in systemic arterial pressures have been associated with increased cardiovascular morbidity and mortality including cardiovascular death, myocardial infarction, heart failure and stroke. It remains one of the most reversible causes of various disease states. This article aims to review current blood pressure (BP) targets and medical therapies for hypertension in the modern era, recognizing varying clinical characteristics such as comorbidities and patient risk profile. (C) 2018 IMSS. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:548 / 557
页数:10
相关论文
共 50 条
  • [21] Introduction to a Compendium on the Pathophysiology and Treatment of Hypertension
    Mancia, Giuseppe
    Hall, John E.
    CIRCULATION RESEARCH, 2019, 124 (07) : 967 - 968
  • [22] New Therapy Update Aprocitentan: An Endothelin Receptor Antagonist for the Treatment of Drug-Resistant Systemic Hypertension
    Airo, Michael
    Frishman, WIlliam H.
    Aronow, Wilbert S.
    CARDIOLOGY IN REVIEW, 2025, 33 (02) : 114 - 119
  • [23] Efficacy and safety of azilsartan medoxomil in the treatment of hypertension: a systematic review and meta-analysis
    Zhu, Ling
    Wei, Guo-Cui
    Xiao, Qing
    Chen, Qian-Lan
    Zhao, Qian
    Li, Xiu-xia
    Pan, Ling-ai
    Xiong, Xuan
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2024, 11
  • [24] Do we over treat mild hypertension?
    Zanchetti, Alberto
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (08) : 1121 - 1126
  • [25] Hypertension in Mexican adults: prevalence, diagnosis and type of treatment. Ensanut MC 2016
    Campos-Nonato, Ismael
    Hernandez-Barrera, Lucia
    Pedroza-Tobias, Andrea
    Medina, Catalina
    Barquera, Simon
    SALUD PUBLICA DE MEXICO, 2018, 60 (03): : 233 - 243
  • [26] New wrinkles in hypertension management 2022
    Carey, Robert M.
    Whelton, Paul K.
    CURRENT OPINION IN CARDIOLOGY, 2022, 37 (04) : 317 - 325
  • [27] Interventional Treatment of Hypertension: A New Paradigm
    Jones, W. Schuyler
    Vemulapalli, Sreekanth
    Patel, Manesh R.
    CURRENT CARDIOLOGY REPORTS, 2013, 15 (05)
  • [28] New Challenges in the Treatment of Disordered Gambling
    Echeburua, Enrique
    Salaberria, Karmele
    Cruz-Saez, Marisol
    TERAPIA PSICOLOGICA, 2014, 32 (01): : 31 - 40
  • [29] Physical activity in the treatment of systemic arterial hypertension
    Mantovani, E.
    Spigolon, L.
    MEDICINA DELLO SPORT, 2009, 62 (02) : 125 - 134
  • [30] Treatment of Mild Hypertension: Seeing Through SPRINT
    Martin, Stephen A.
    AMERICAN FAMILY PHYSICIAN, 2023, 108 (02) : 122 - 124